Formulation and Characterization of Isradipine as Oral Nanoemulsion

Noor A. Sadoon* and Mowafaq M. Ghareeb**

* Ministry of Health and Environment, Baghdad, Iraq.
** Department of Pharmaceutics, College of Pharmacy, University of Baghdad, Baghdad, Iraq.

Abstract

Isradipine related to dihydropyridine (DHP) class of calcium channel blockers (CCBs). It is used to treat hypertension, angina pectoris, as well as Parkinson disease. It goes under the BCS class II drug (low solubility-high permeability). The drug will experience extensive first-pass metabolism in liver, thus, oral bio-availability will be approximately 15 to 24%.

The aim of the study is preparing stable oral oil in water (o/w) nanoemulsion of isradipine to promote the colloidial dispersion of isradipine in the nano range, so that it may be absorbed by intestinal lymphatic transport in order to avoid hepatic first-pass metabolism (isradipine undergoes 15-24% first pass metabolism) and increase drug bioavailability.

The solubility study was carried out in various vehicles for selecting best solvent for dissolving isradipine. Pseudo-ternary phase diagrams is formed at (1:1, 1:2, 1:3, 1:4 and 2:1) ratios related to Smix (co-surfactant and surfactant). There are 11 nano-emulsion was prepared through the use of many concentrations of (Transcutol, Tween20, and Triacetin).

All formulations assessed for (in-vitro drug dissolution, pH measurement, viscosity, drug content, polydispersity index, particle size distribution, thermodynamic stability, dye test, and light transmittance). It is indicated that the extent as well as the rate of release regarding all the prepared formulations have considerably higher in comparison to that of crude drug powder. Results of characterization were explained that isradipine nano emulsion (NE9) with Smix (1:4) : oil : deionized water (40:5:55) ratio was the optimized formula that has droplet size range (177.1nm), the lowest value of polydispersity index (0.12), the highest percent of drug content (99.7%) typical pH value for oral administration (5.21), good percent of light transmittance (99.86 %), the range of viscosity (65.12 - 25.2 m Pas. sec.) was suitable for oral administration, also the isradipine’s in vitro release has been considerably higher. It can be concluded that nano emulsion drug delivery system (DDS) can be considered as an encouraging method for improving the stability, dissolution and solubility of formulation.

Keywords: Nanoemulsion, Isradipine, Pseudoternary phase diagrams.

Iraqi Journal of Pharmaceutical Sciences

DOI: https://doi.org/10.31351/vol29iss1pp143-153

*Corresponding author E-mail: noorabdallah9089@yahoo.com
Received: 21/9/2019
Accepted: 23/11/2019

143
**Introduction**

Low Dissolution rate and partial absorption will be generally seen in drugs with low permeability and low water solubility (1). Pharmaceutical research focuses on two fields to improve the oral bio-availability, which are: (i) enhance the dissolution rate as well as the solubility for drugs with low water-solubility, (ii) enhance the permeability related to drugs with low permeability (2).

Solubility can be defined as a major parameter used for the purpose of achieving the required drug’s concentration in a systemic circulation for pharmacological response (3). Several methods were modified for resolving the drug’s poor aqueous solubility (4). There is high permeability and poor water solubility in the class II drugs according to BSC (5,6).

Distinctive approaches for the drug’s solubilization are hydrotropy, complexionation, pH adjustment, chemical modification, micrionization, co-solvency, solid dispersion, and micellar solubilization.

Nano emulsions can be defined as new which might occur as oil-in-water (o/w) or water-in-oil (w/o) structure, in which the molecule’s centre is oil or water, respectively with droplet diameters of range (50-1000nm), the average size of the droplet range between (100 and 500nm) (7).

The nano-emulsions drug delivery are the best routes because of their capacity for dissolving large quantities of the low soluble drugs, also due to their common compatibility and ability for protecting drugs from hydrolysis and enzymatic degradation (8).

The small size of the nano-emulsion’s droplet are more clear transparent appearance which are definitely different from the milky-white color related to coarse emulsion (in which the micron-sized droplets are factors in the multiple light scattering) (9).

Nano emulsions are kinetically stable but thermodynamically unstable, with Ostwald ripening being the main factor of their instability (10, 11, 12).

Isradipine belongs to DHP class of CCBs, and it binds to the calcium channels with specificity and affinity to inhibit the calcium flux into cardiac and arterial smooth muscle cells (13). It is used in prophylactic treatment of angina pectoris, treatment of hypertension, some currently studies have indicated that isradipine in the treatment of Parkinson’s disease (14,15).

Isradipine is considered to be freely soluble in methylene chloride, acetone, chloroform; soluble in ethanol; insoluble in water (<10 mg/L at 37°C) (16). It is mainly absorbed from gastrointestinal tract following oral administration, experiences some extensive first-pass metabolism; therefore bio-availability is (15 to 24%) (17).

**Materials and Methods**

Isradipine, triacetin, cremphore EL and transcutol were purchased from Hyperchem company, china, tween 80 and tween 20 have been bought from Thomas baker (chemicals) Pvt Ltd, India. Castor oil obtained from Evans medical Ltd, United Kingdom. Olive oil supplied by Pomace olive oil oilex, S.A. Spain, coconut oil, cinnamon oil obtained from Shaanxi Guanjie Technology CO, LTD, China. Liquid paraffin obtained from Merck, Germany. Polyethylene glycol 400,200 supplied by M/s provizer pharma. India. Methanol supplied by Avantor performance materials, Norway. Hydrochloric acid from Grim land chemical comp, United Kingdom. Na2HPO4, KH2PO4 and deionized water were supplied by Janeen for chemical and laboratory materials, Baghdad, Iraq.

**Methods**

- **Differential scanning calorimeter (DSC)**

  The thermal properties of drug powder samples were examined via the use of DSC /TA-60 thermal analysis controller with the intercooler-2 cooling system(DSC-60, Shimadzu, Japan). Sample heating was run for each sample set for 50-250°C at the rate of 10°C/min, using nitrogen as blank gas (18).

- **Solubility study of isradipine**

  The solubility of isradipie measured in different oils which are coconut oil, liquid paraffin, cinnamon oil, castor oil, olive oil, Triacetin, the surfactants which are tween 80, tween 20 and cremphore EL and co-surfactants which are glycol polyethylene glycol 200,400 and transcutol. Excess amounts of the isradipine powder was added to 5ml of each oil, co-surfactants and surfactant in small plain tubes. Then, these tubes were tightly closed and placed in isothermal shaker water bath at 25 ± 0.5°C for 48 hr. After this time, samples were centrifuged at 3000 rpm for 20 minutes, then the supernatant layer for each sample filtered by using filter membrane (0.45 µm). After filtration, samples were diluted with methanol, the solubility evaluated at λ max at 326nm through the use of UV-visible spectrophotometer and the measurement carried out in triplicate (19,20).

- **Construction of pseudo-ternary phase diagrams**

  Components related to the pseudo-ternary phase diagrams consist of oil, mixture of surfactant and co-surfactant (S mix) as well as deionized water prepared through the
use of aqueous titration approach\(^{(21)}\). Co-surfactant and surfactant were mixed in various ratios (1:1, 1:2, 1:3, 1:4, 2:1). With regard to each one of the phase diagrams, oil as well as the S mix were blended in various weight ratios until obtaining the maximum ratio of S mix and oil. There were 11 different combinations related to S mix and oil that have been prepared, such combinations were slowly titrated with aqueous phase (deionized water), each mixture was titrated with deionized water under gentle magnetic stirrer without heating. The concentration of water at which transparent-turbid changes occurred was measured as the endpoint of the titration \(^{(22)}\).

**Thermodynamic stability studies**\(^{(23)}\)

All formulations that were prepared were exposed to various thermodynamic stability tests (freeze-thaw cycle, heating-cooling cycle and centrifugation) for overcoming choosing metastable formulation.

**Centrifugation test**

All the prepared nanoemulsion formulations were centrifuged at 3500 rpm for (20-30 minutes) and assessed for cracking, creaming, and phase separation.

**Heating-cooling cycle (H/C cycle)**

There are 6 cycles between (4-45°C) with storage at each one of the temperatures for 48hr. Formulations, that are considered stable at such temperatures, were subjected to freeze-thaw cycle.

**Three freeze-thaw cycles**

between (-21 and +25°C) with storage at each one of the temperatures for 48hr determined for all the prepared nano-emulsion formulations.

**Droplet size measurement**

An amount of 0.1 ml of each formula was dispersed in fifty milliliters of deionized water in volumetric flask, after that subjected to mixing process via inverting the flask. Globule size has been assessed via particle size analyzer which analyzed fluctuations in the light scattering because of particle’s Brownian motion. Light scattering has been inspected at 25°C at a 90° angle \(^{(24)}\).

**Polydispersity index (PDI)**

This assay is used to measures uniformity related to the globules size in nano-emulsion. It could be obtained by ABT-9000 nanolaser particle size analyzer. Higher polydispersity value indicates lower uniformity of globules size of nano-emulsion \(^{(25)}\).

**Measurement of pH**

The pH of all prepared nano-emulsion formulas was determined with the use of digital pH meter utilizing (20-30ml) sample placed in 50-ml capacity beaker \(^{(26)}\). All the measurements have been repeated 3 times. The pH value is of high importance to determine the nano-emulsion’s stability since the pH alteration mean the occurrence of the chemical reactions which could damage the final product’s quality.

**Percent of light transmittance measurement (%T)**

Measurement of the %T was achieved for eleven control nano-emulsions at 650nm, while the distilled water kept as blank \(^{(27)}\).

**Viscosity determination**

The viscosity of sample was determined without dilution with the use of NDJ-5S digital viscometer and spindle number (2), the spindle has been inserted in (30-40ml) of the prepared NE sample in graduated beaker and revolved at distinctive speeds which have been (6, 12, 30 and 60 rpm) \(^{(28)}\).

**Dye test**

Water-soluble dye (methyl orange) was mixed with each one of the isradipine NE formulations. In the case when the dye is mixed with nano-emulsion homogenously without precipitation, this will indicate that the continuous phase is water and nano-emulsion structure is o/w \(^{(29)}\).

**Drug content**

Drug content was determined via UV visible spectrophotometer. Formulation diluted with methanol to the needed concentrations, and absorbance was determined at wave length against solvent blank. Drug content was calculated by employing the following equation \(^{(30)}\).

\[
\text{Drug content} = \frac{\text{Analyzed content}}{\text{Theoretical content}} \times 100
\]

**In vitro dissolution study**

In vitro drug release of all prepared nano-emulsion formulations were assessed via the use of USP dissolution apparatus-II (paddle approach). Dissolution medium, on the basis of monograph of isradipine in USP, is 0.1N HCl as dissolution media (500ml), at 37±0.5°C and 50 rpm \(^{(31)}\) through the use of dialysis bag technique (Molecular cut off 12000 Da) \(^{(32)}\), formula that contain isradipine equivalent to single dose has been placed in dialysis bag, also 5ml of the dissolution medium has been taken. The time intervals for drawing out aliquots have been 5, 10, 15, 30, 45, 60, 90 and 120 min \(^{(33)}\).

**Zeta potential measurement**

Zeta potential can be defined as a parameter that is applied for measuring surface charge properties and as a sign of a physical stability related to the nano-emulsions \(^{(34)}\).
Fourier transform infrared spectroscopy (FTIR)
Compatibility of drug and formulation was determined by FTIR. The spectrum was obtained for (drug, tween 20, transcutol, triacetin, and selected formula). It is used for identifying the functional groups with their means of attachment, and the fingerprint of the molecule. The sample can be prepared by employing a suitable method such as potassium bromide pellet method, Nujol mulls, and then the sample is scanned in FTIR at a moderate scanning speed between 4000-400 cm⁻¹.

Field Emission Scanning Electron Microscope (FESEM)
Isradipine nanoemulsions were also analyzed by field emission scanning electron microscope (FESEM). It is apparatus that used for an image surface roughness analysis, used to explain the shape, size droplets within formulated nanoemulsion of isradipine.

Statistical analysis
The results of the study indicate the average of triplicate readings for each sample. Analysis of variance test (ANOVA) were applied to investigate that the results of study considered as significant results when (P< 0.05) and the results were considered not significant when (P> 0.05).

Results and Discussion
Study of differential scanning calorimetry (DSC)
The measured melting point via DSC is used to confirm the purity of the drug used in the study. The sharp peak appeared in figure 1 referred to melting point of the drug and indicated the crystalline drug in nature.

Solubility study
Selection of the main constituents (cosurfactant, surfactant and oil) in preparation of nanoemulsion has been considered as an essential factor in formulation development, since the nano-emulsion ability of maintaining drug in solubilized form has been considerably impacted via the drug’s solubility in oil phase. The isradipine’s solubility was indicated to be highest in triacetin (81 mg/ml) in comparison to other oils in table 1. With regard to the Smix part, high drug solubility in transcutol(75.1 mg/ml) and tween20(20.101 mg/ml) in table 2. Although the drug solubility considered also high in PEG200, PEG400, transcutol was selected as a cosurfactant due to its higher solubility, better miscibility and giving good nanoemulsion region in pseudo ternary phase diagram compared with PEG200, PEG400.

| Oil              | Solubility (mg/ml) mean ±SD* |
|------------------|-----------------------------|
| Castor oil       | 4.135± 0.15                 |
| Coconut oil      | 12.744± 0.04                |
| Cinnamon oil     | 7.112± 0.03                 |
| Triacetin oil    | 81.000± 0.05                |
| Olive oil        | 4.102± 0.01                 |
| Liquid paraffin  | 1.123 ±0.12                 |

Table 2. Saturation solubility of isradipine in different surfactant/ cosurfactant

| Surfactant/ cosurfactant | Solubility (mg/ml) mean ±SD* |
|--------------------------|-----------------------------|
| Tween 20                 | 20.101± 0.28                |
| Tween 80                 | 5.601± 0.02                 |
| Cremphore EL             | 12.100 ± 0.03               |
| PEG 200                  | 40.10 ± 0.09                |
| PEG 400                  | 35.013± 0.05                |
| Transcutol               | 75.101± 0.154               |

Pseudo-ternary phase diagram construction
The components of the pseudo-ternary phase plot are (oil, deionized water and Smix surfactant/co-surfactant, which considered as a variable component due to that, it presents in various (surfactant /co-surfactant) ratio such as 1:1, 2:1, 1:2/1:3 and 1:4. In the pseudo-ternary phase plot, the shaded area represents the area of nanoemulsions while unshaded area represents the area of the emulsion.

Pseudo-ternary phase diagram plot for different Smix ratio Tween 20: Transcutol are shown in figure (2). In Smix 2:1 when concentration of surfactant was increased as related to cosurfactant, nano-emulsion area reduced in comparison to the Smix ratio 1:2. cosurfactant concentration at Smix (1:2/1:3,1:4) rises in the nanoemulsion region more than in Smix ratio (2:1).

Figure 1. Differential scanning calorimetry of isradipine.
Isradipine nanoemulsions

Preparation of isradipine loaded nanoemulsion

The quantity of isradipine (0.025) gram that required for preparation of (100) gram formula dissolved in the specialized quantity of triacetin, then S mix ratio was added to the oil and isradipine mixture and the whole mixture mixed with the use of vortex mixer for 5 minutes, then deionized water titrated drop by drop up to 100 gm which is the final weight of the formula, so nine formulas of nanoemulsion (o/w) were produced. All of the nanoemulsion formulation were clear and transparent.

Table 3. Formulation of different isradipine loaded nanoemulsion

| Formula No. | S mix ratio | % w/w of a component of nanoemulsions |
|-------------|-------------|--------------------------------------|
|             | S mix(Tween20,Transcutol) | Oil | Water | Drug |
|             | S mix(Surfactant:Cosurfactant) | Tricetin | Deionized water | Isradipine |
| N1          | 1:1         | 40   | 10   | 50   | 0.025 |
| N2          | 1:1         | 55   | 5    | 40   | 0.025 |
| N3          | 1:2         | 40   | 5    | 55   | 0.025 |
| N4          | 1:2         | 45   | 10   | 45   | 0.025 |
| N5          | 1:3         | 40   | 5    | 55   | 0.025 |
| N6          | 1:3         | 45   | 10   | 45   | 0.025 |
| N7          | 1:4         | 35   | 5    | 60   | 0.025 |
| N8          | 1:4         | 30   | 10   | 60   | 0.025 |
| N9          | 1:4         | 40   | 5    | 55   | 0.025 |
| N10         | 1:4         | 45   | 5    | 50   | 0.025 |
| N11         | 2:1         | 35   | 5    | 60   | 0.025 |
Thermodynamic stability studies

All of the prepared nanoemulsions formulations passed the thermodynamic stability test, that is (freeze-thawing test, heating-cooling test, and centrifugation test) in order to get thermodynamic stable formulations of nanoemulsions that have no creaming, cracking and phase separation which may present in the macroemulsion\(^{39}\). The thermodynamic results of the prepared formulation were shown in table 4.

Table 4 . Thermodynamic stability of isradipine loaded nanoemulsion

| Formula code | Centrifugation test | Heating-cooling cycle test | Freeze-thawing cycle test |
|--------------|---------------------|---------------------------|--------------------------|
| NE1          | pass                | pass                      | pass                     |
| NE2          | pass                | pass                      | pass                     |
| NE3          | pass                | pass                      | pass                     |
| NE4          | pass                | pass                      | pass                     |
| NE5          | pass                | pass                      | pass                     |
| NE6          | pass                | pass                      | pass                     |
| NE7          | pass                | pass                      | pass                     |
| NE8          | pass                | pass                      | pass                     |
| NE9          | pass                | pass                      | pass                     |

Particle size measurement\(^{40}\)

It has been indicated that the systems which consist of 10 percent triacetin created nano-emulsion with larger particle size in comparison with the systems consisting of five percent triacetin. High surfactant ratios enabled interfacial film to stabilize and condense, while the film will increase with the increase in cosurfactant concentration.

Small mean droplet size might be related to penetration of the co-surfactant molecules into surfactant film. This might reduce the interfacial film’s surface, which might lower radius of curvature of droplets and forming transparent systems. Therefore, relative proportion of surfactant to co-surfactant has different impact on droplet size.

Polydispersity index (PDI)\(^{40}\)

Polydispersity of all the formulations has been not more than (0.5), which indicates uniform and narrow globule size distribution, as can be seen in table(3).

Determination of pH

The pH related to all the formulations have been determined via pH meter in triplicate at 25 ± 1 °C and indicated to be in range of (4.9-5.21 ) as can be seen in the table (3) . The higher pH value in the formulations of isradipine nanoemulsions was (5.21) for NE9 and this pH value is suitable for oral administration.\(^{41,44}\).

Measurement of light transmittance

Values of transmittance percentage shown in table 5 are close to 100% specified that all formulations were transparent, clear, and transmit light efficiently\(^{42}\).

Table 5. Characterization of isradipine loaded nanoemulsion where, mean droplet size,polydispersity, pH and %T (mean ± SD, n= 3)

| Formula code | Mean droplet size | Polydispersity | PH measurement | Light transmittance |
|--------------|-------------------|----------------|----------------|---------------------|
| NE1          | 297.7 ±0.01       | 0.345±0.00    | 5.120± 0.091  | 97.145± 0.1321      |
| NE2          | 315.7 ±0.01       | 0.363±0.00    | 4.910± 0.0652 | 98.298± 0.0235      |
| NE3          | 98.4 ±0.011       | 0.217±0.00    | 5.071± 0.008  | 98.512± 0.0041      |
| NE4          | 358.2 ±0.21       | 0.271±0.00    | 4.811± 0.0026 | 97.223± 0.008       |
| NE5          | 260.0 ±0.01       | 0.333±0.00    | 4.8143± 0.008 | 99.617±0.0046       |
| NE6          | 357.8 ±0.01       | 0.005±0.00    | 4.912± 0.0087 | 98.387± 0.0043      |
| NE7          | 255.0 ±0.01       | 0.215±0.00    | 5.111± 0.003  | 98.411± 0.0076      |
| NE8          | 186.2 ±0.21       | 0.213±0.00    | 4.517± 0.001  | 99.125± 0.15        |
| NE9          | 177.1 ±0.01       | 0.121±0.00    | 5.214± 0.009  | 99.878± 0.035       |
| NE10         | 287.1 ±0.12       | 0.341±0.00    | 5.140± 0.067  | 98.690± 0.034       |
| NE11         | 413.0 ±0.10       | 0.301±0.00    | 4.910± 0.0013 | 97.121± 0.061       |
Viscosity measurement

The results of the viscosity of isradipine nanoemulsions were found to be in range (25.026 – 300.782 mPa.sec.). It was observed that all formulations have low viscosity and this important to ensure pourability, packing, especially if the nanoemulsion dedicated for oral use (43). When the rotation speed increased (velocity), the viscosity decreased indicating the pseudoplastic (shear thinning liquids) flow of the preparation (44).

Dye test

Methyl orange is an azo dye miscible with water. Following the addition of methyl orange dye, it has been shown that the dye miscible with all the isradipine NE formulations; no cumulative or cluster was formed (44).

Drug content estimation

The drug content related to all prepared isradipine nano-emulsions was more than 95% and there has been no considerable difference between different formulations (p > 0.05), which meet British pharmacopia requirement and were within an acceptable range (95.0%-105.0%), which indicates that there has been no precipitation of drug in any of prepared formulations (40).

In vitro drug release

Pure drug showed (40.45%) drug release at end of sixty minute because of its low aqueous solubility.

With nanoemulsion formulation, it was noticed as the concentration of transcutol increase, the release is high reach 100% at the end of dissolution test, the reason behind this is due to the effect of co-surfactant which are good solubilizing and facilitating dissolution process of the pure drug (46, 47).

At the same time, NE9 showed highest release; end of sixty minutes, that could be the result high content of transcutol.

Co-surfactant role in nano-emulsion systems decrease interfacial tension and increases the interface’s fluidity. Also, it increases the hydrocarbon tail’s mobility and enable greater penetration of the oil in nanoemulsion region (48).

![Figure3. Effect of Smix:oil ratio on release profile where (A) release of NE1, NE2 and pure drug (B) release of NE3, NE4 and pure drug (C) release of NE5, NE6 and pure drug, (D) release of NE7, NE8, NE9, NE10 and pure drug (E) release of NE11 and pure drug](image-url)
Selection of optimized formula of isradipine nanoemulsions

According to the characterization study of the prepared nanoemulsions, there was an indication that the (NE9) is the optimized formula, because it is characterized by good droplet size (177.1), low PDI (0.120), best pH value for oral use (5.214), good percent transmittance (99.96), percent of drug content was higher (98.9), accepted viscosity range for oral use (25.026 – 65.12 mPa.sec) and highest release of isradipine from the formula. The optimized formula would be subjected to further studies such as zeta potential, drug – excipient compatibility, field emission scan electron microscope (FESEM).

Zeta potential measurement

The value of optimized formula was (-18.3).

Studies of Drug-Excipient Compatibility study by Fourier Transformed Infrared Spectroscopy (FTIR) Pure isradipine exhibited characteristic peaks at 3,348 cm\(^{-1}\), (N-H stretching), 2,945 cm\(^{-1}\), (C-H stretching), 2,358 cm\(^{-1}\), (O-H stretching), 1,701 cm\(^{-1}\), (C=O stretching), and 1,448 cm\(^{-1}\), (C=C stretching) (Figure 5). All these peaks had appeared in FTIR spectrum of nanoemulsion formulation. This indicates that there was drug – excipient compatibility between all components of prepared nanoemulsion.

---

**Figure 4.** Effect surfactant:cosurfactant ratio on release profile of isradipine nanoemulsion (NE1, NE3, NE5, NE9, NE11) and pure isradipine.

**Figure 5.** Zeta potential for NE9 formula.

**Figure 6.** FTIR spectrum of isradipine powder.
Field emission scan electron microscope (FESEM)

Figure 7 shows that oil droplets of the optimized formula are spherical in shape and there are accumulation of smaller oil droplet, however, there was no main changes in shape and size of the oil droplets upon accumulation (35).

Conclusions

From this study, it is concluded that nanoemulsion provided an important dosage form for the oral water-insoluble drug. NE that was prepared from triacetin oil, tween 20 and transcutol was encouraging method for improving dissolution rate and solubility of isradipine. The present study may serve as a prototype approach for the formulation development of other hydrophobic drugs nanoemulsion drug delivery system.

Acknowledgements

The authors would like to thank Department of Pharmaceutics, College of Pharmacy, University of Baghdad for the completion of research.

References

1. Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug discovery today. 2007 Dec 1;12(23-24):1068-75.
2. Serajuddin A, Sheen PC, Agustine MA. Improved dissolution of a poorly water soluble drug from solid dispersion in polyethene glycol; polysorbate 80 mixtures. J Pharm Sci. 1990; 79:463-464.
3. Deshmukh AS, Mahale VG, Mahajan VR. Liquisolid compact techniques: A Review. Research Journal of Pharmaceutical Dosage Forms and Technology, 2014; 6(3): 161-166.
4. Goyal U, Gupta A, Chand Rana A, Aggarwal G. Self Microemulsifying Drug Delivery System: A Method for Enhancement of Bioavailability. International Journal of Pharmaceutical Sciences and Research, 2012; 3(1): 66-79.
5. Mahale VG, Deshmukh AS, Mahajan VR. Formulation and Characterization of Inclusion Complexes: A Review. Pharmtechmedica, 2014; 3(3): 476-480.
6. Deshmukh AS. Recent advances in self emulsifying drug delivery system. International Journal of Pharmaceutical Sciences and Nanotechnology, 2015; 8(1): 1-5glycol; polysorbate 80 mixtures. J Pharm Sci. 1990; 79:463-464.
7. Chime SA, Kenchukwu FC, Attama AA. Nanoemulsions—advances in formulation, characterization and applications in drug delivery. In Application of nanotechnology in drug delivery 2014 Jul 25.

8. Ravi T P U, Padma T (2011) Nanoemulsions for drug delivery through different routes. Res. Biotechnol. 2(3): 1-13.

9. M.E. Aulton, K.M. Taylor, Aulton’s pharmaceutics: the design and manufacture of medicines, Elsevier Health Sciences, 2013.

10. Yukuyama MN, Ghisleni DD, Pinto TJ, Bou-Chacra NA. Nanoemulsion: process selection and application in cosmetics - a review. Int J Cosmet Sci 2016; 38(1): 13-24.

11. Rodriguez-Aller M, Guillarme D, Veuthey JL, Gurny R. Strategies for formulating and delivering poorly water-soluble drugs. J Drug Deliv Sci Technol 2015; 30(B): 342-51.

12. Fryd MM, Mason TG. Advanced nanoemulsions, Annu Rev PhysChem 2012; 63: 493-518.

13. Rang HP, Dale MM, Ritter JM, and Flower RJ. Rang & Dale’s Pharmacology; 6th Edn; Churchill Livingstone Elsevier, London, 2008; 557-574. 2014.

14. Bennett PN, Brown MJ. Clinical pharmacology; 9thEdn; Churchill Livingstone Elsevier, London, 2003; 461-496 3.

15. Kim, W. C., Oh, S. H., Kim, S. H., Kim, O. J., Lee, M. S. Parkinsonism and related disorders. Amsterdam:Elsevier Science 2007, (pp. 113–140).

16. Moffat A, Osselton M, Widdop B. Clarke’s Analysis of Drugs and Poisons. 4th edition. The Pharmaceutical Press 2011; p-1536.

17. Sweetman SC. Martindale: the complete drug reference. 36th ed. London: Pharmaceutical press; 2009. Cardiovascular drugs. Volume 1. Monographs on drugs and ancillary substances. p. 1319.

18. Adriano Antunes . Determination of the melting temperature, heat of fusion, and purity analysis of different samples of zidovudine using DSC. Brazilian Journal of Pharmaceutical Sciences. 2010; (46) : 1.

19. Yeramwar S, Patil S, Sharma P, Bhargava A. Design & development of solid self micro-emulsifying osmotic drug delivery system for isradipine. Journal of Drug Delivery and Therapeutics. 2014 Jun 23:28-41.

20. Shelar DB, Pawar SK, Vavia PR. Fabrication of isradipine nanosuspension by anti-solvent microprecipitation–high pressure homogenization method for enhancing dissolution rate and oral bioavailability. Drug delivery and translational research. 2013 Oct 1;3(5):384-91.

21. Schalbart , M. Kawaji , K. Fumoto. Formation of tetradecane nanoemulsion by low-energy emulsification methods . International journal of refrigeration. 2010; 33:1612-1624.

22. Ghareeb MM, Neamah AJ. Formulation and characterization of nimodipine nanoemulsion as ampoule for oral route. International Journal of Pharmaceutical Sciences and Research. 2017 Feb 1;8(2):591.

23. R.B.D. Reddy, C.T.L. Kumari, G.N. Sowjanya, S.L. Sindhuri, P. Bandhavi Nanoemulsions an emerging trend IJPRD, 4 (06) (2012), pp. 137-152.

24. Sohn Y, Lee SY, Lee GH, Na YJ, Kim SY, Seong I, Lee BJ, Kuh HJ, Lee J. Development of Self-micro Emulsifying Bilayer Tablets for pH-Independent Fast Release of Candesartan Cilexetil. Die Pharmazie-An Inter J of Pharm Sci 2012; 67(11) :917-924.

25. Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK, Ali M. Development and bioavailability assessment of ramipril nanoemulsion formulation. European Journal of Pharmaceutics and Biopharmaceutics. 2007 May 1;66(2):227-43.

26. Aruna K, Aggarwal G, Harikumar SL. Nanotechnology in novel drug delivery system. J of Drug Deliv and Therap. 2014; 4(5), 21-28.

27. Mohammad Sajid Ali , Mohammad Sarfaraz Alam . Preparation characterization and stability study of dutasteride loaded nanoemulsion for treatment of benign prostatic hypertrophy. Iran J Pharm Res. 2014;13(4):156-163.

28. Pratiwi L, Fudholi A, Martien R, Pramono S. Design and optimization of self-nanoemulsifying drug delivery systems (SNEDDS) of ethyl acetate fraction from mangosteen peel (Garcinia mangostana, L.). Inter J of PharmTech Res. 2016;9(6): 380-387.

29. Srilatha R, Aparna C, Srinivas P, Sadanandam M. Formulation, evaluation and characterization of glipizide nanoemulsions. Asian J Pharm Clin Res 2013;6:66-71.

30. Srinivas Domalapally, A. Indira Revathi, S. Jaya and N. Divya Teja. Enhancement of dissolution profile of poorly water soluble...
drug (nimodipine) by using liquisolid compact technique. Inter J of Pharma Sci. 2014; 4(1): 447-456.

31. Harika K, Debnath S, Babu MN. Formulation and evaluation of nanoemulsion of amphotericin B. International Journal of Novel Trends in Pharmaceutical Sciences. 2015;5(4).

32. British Pharmacopoeia XXX. London: Medicines and Healthcare products Regulatory Agency. 2016. p741

33. Manyarara TE, Khoza S, Dube A, Maponga CC. Formulation and characterization of a paediatric nanoemulsion dosage form with modified oral drug delivery system for improved dissolution rate of nevirapine. MRS Advances. 2018;3(37):2203-19.

34. Kumar R, Soni GC, Prajapati SK. Formulation development and evaluation of Telmisartan Nanoemulsion. IJRDPL. 2017;6:2711-9.

35. Affandi MM, Julianto T, Majeed A. Development and stability evaluation of astaxanthin nanoemulsion oral liquid dosage form. Int J Pharm Pharm Sci. 2015;7(12):209-16.

36. Park JB, Lee GH, Kang JW, Jeon IS, Kim JM, Kim KB, Kang CY. Improvement of photostability and dissolution profile of isradipine using inclusion complex. Journal of Pharmaceutical Investigation. 2013 Feb 1;43(1):55-61.

37. Azeem A, Rizwan M, Ahmad FJ, Izqbal Z, Khar RK, Aqil M, Talegaonkar S. Nanoemulsion components screening and selection: a technical note. Aaps PharmScitech. 2009 Mar 1;10(1):69-76

38. Lawrence M.J., Rees G.D. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev. 2000;45:89–121. doi: 10.1016/S0169-409X(00)00103-4.

39. Bhiaskapathi D, Madhukar P, Kumar BP and Kumar GA. Formulation and characterization of pioglitazone hcl self emulsifying drug delivery system. der pharmacia lettre. 2013; 5(2): 292-305.

40. Ibrahim E, Sokar MS, Bahey-El-Din M, Shaker DS. Enhanced transdermal permeability of Terbinafine through novel nanoemulgel formulation: Development, in vitro and in vivo characterization. Future Journal of Pharmaceutical Sciences. 2018 Jun 1;4(1):18-28.

41. Drais HK, Hussein AA. Formulation and characterization of carvedilol nanoemulsion oral liquid dosage form. Int J Pharm Pharm Sci. 2015;7(12):209-16.

42. Dharmang Pandya, Bhavin Rana, nilay solanki. Oral Bioavailability Enhancement of Bromocryptine Mesylate by Self-micro Emulsifying Drug Delivery System (smeds). Int j Pharm Pharm Sci 2016 ; 8(6) :76-81.

43. Miller Dave A., McGinity James W. Aqueous Polymeric Film Coating, In: Augsburger Larry L., Hoag Stephen W.(eds.) Pharmaceutical Dosage Forms:Tablets. Third edition 2008, New York: Informa Health Care: 424-425.

44. Lawrence M.J., Rees G.D. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev. 2000;45:89–121. doi: 10.1016/S0169-409X(00)00103-4.

Baghdad Iraqi Journal Pharmaceutical Sciences by biips is licensed under a Creative Commons Attribution 4.0 International License. Copyrights© 2015 College of Pharmacy - University of Baghdad.